The shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market

Davis Polk advised the representatives of the several underwriters in connection with Oculis Holding AG’s follow-on SEC-registered offering of an aggregate of 5,000,000 ordinary shares. The offering resulted in gross proceeds of $100 million for Oculis. Oculis’s ordinary shares are listed on the Nasdaq Global Market and the Nasdaq Iceland Main Market under the symbol “OCS.”

Oculis is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’s highly differentiated pipeline of multiple innovative product candidates in development includes: OCS-01, a topical eye drop candidate for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate for acute optic neuritis with potentially broad clinical applications in other neuro-ophthalmic diseases; and Licaminlimab (OCS-02), a topical biologic anti-TNFα eye drop candidate for dry eye disease.

The Davis Polk corporate team included partner Derek Dostal, counsel Arisa Akashi Sin and associate Megan P. Phansalkar. The tax team included partner Ethan R. Goldman and associate Valentin Van de Walle. The intellectual property team included partner David R. Bauer and associates Jordan Khorshad and Elizabeth Pott. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

 

Copy link to share post